Current epidemiologic and genetic data suggest the hypothetical paradigm that prostate cancer occurs in three forms: sporadic, familial, and hereditary ( Figure 1 ). Sporadic cases are not associated with familial inheritance patterns, while familial cancer is de®ned as simple clustering of two or more cases within a family. The existence of hereditary prostate cancer, a subset of the familial form, is suggested by three epidemiologic observations enumerated by Carter et al 1 :
(1) relatives of patients younger than 55 y are at higher risk of getting prostate cancer than those with older affected relatives; (2) there is stronger familial clustering in families with early onset of prostate cancer; and (3) the number of affected family members and their age at onset are the most important determinants of risk among relatives. 1 It has been estimated that the hereditary form of this disease accounts for 43% of early onset cancers (age 55 y or younger) but only 9% of all prostate cancer occurring by age 85 y. 2 Eeles et al 3 have summarized the published literature concerning familial clustering of prostate cancer. In casecontrol studies the relative risk of prostate cancer in ®rst-degree relatives of affected men ranges from 1.76 ± 11. In studies comparing the percentage of cases vs controls with a positive family history of prostate cancer, the relative risk ranges from 0.64 ± 7.5. Cohort studies in the United States 4 and Sweden 5 estimate relative risks of prostate cancer of 2.2 and 1.70, respectively, in men with affected relatives. Using segregation analysis in nuclear families Carter et al 1 estimated hazard ratios ranging from 1.4 ± 7.1 depending upon the age of the proband and the number of affected relatives (Table 1) . This analysis suggests hereditary prostate cancer is caused by a rare gene or genes with high penetrance and dominant inheritance.
Using a genome-wide search in 66 high-risk families each with three or more affected ®rst-degree members, Smith et al 6 reported linkage for prostate cancer risk to a genetic susceptibility locus on the long arm of chromosome 1 (1q24-25) tentatively called HPC1 (Human Prostate Cancer 1). One additional study has con®rmed linkage to this region in 59 families and noted that African ± American families contributed disproportionately to the evidence for linkage to this site. 7 Two other studies of 136 and 49 high-risk families have not con®rmed linkage at 1q24-25, although neither study included African ± Americans and the larger study contained fewer affected individuals per family on average than the other studies. 8, 9 Together these studies suggest that HPC1 accounts for at least some cases of hereditary prostate cancer, especially in those families with four or more affected relatives. Estimation of the overall proportion of hereditary disease referable to HPC1 and the relative contribution of this locus in various ethnic groups must await further study. Linkage at another site on chromosome 1 at 1q42.2-43 has recently been reported in 47 French and German families. 10 Initial observations suggested that the phenotypes of sporadic, familial, and hereditary prostate cancer are indistinguishable. Bastacky et al 11 reported no differences between patients in these groups undergoing radical prostatectomy with respect to clinical stage, preoperative serum PSA, PSA density, prostate weight, Gleason's sum, pathologic stage, or tumor histology. Furthermore, comparison of outcomes after prostatectomy in a small number of patients with sporadic versus hereditary disease matched for grade and pathologic stage revealed no differences in biochemical relapse free survival (bFRS) at 10 y after therapy. 12 Recently, however, we observed that patients with localized prostate cancer who reported a positive family history had a worse outcome at three and ®ve years after either external beam radiotherapy or radical prostatectomy than those with sporadic cancers. 13, 14 This observation suggests that familial prostate cancer may be more aggressive than the sporadic form and has potentially important implications for screening, treatment, and prevention of prostate cancer in men with a positive family history.
Our initial study included 1038 patients treated for localized prostate cancer between January 1987 and March 1996 by either radical prostatectomy or radiotherapy. 12 All patients had family history evaluated at the time of presentation, with a positive family history de®ned as prostate cancer in a ®rst degree relative (father or brother). Eleven percent of the study population reported a positive family history. The outcome of interest was biochemical relapse free survival (bRFS). Biochemical relapse was de®ned as detectable PSA levels ( b 0.2 ng/ ml) for prostatectomy patients and two consecutive rising PSA levels after nadir for radiation therapy patients. Four hundred and ®fty-®ve patients underwent surgery and 583 were treated with radiation therapy with a median follow up of 27 months. The patients in this study comprised a typical population of patients with localized prostate cancer undergoing therapy with 67% having clinical stage Tlc or T2a, 56% having a pretreatment PSA less than 10 ng/ml, 68% with biopsy Gleason's sum 6 or less, and 65% of the patients under the age of 69 y.
In univariate statistical analysis, only age at the time of diagnosis was associated with the presence of a positive family history (P`0.001) ( Tables 2 and 3 ). Clinical stage, pretreatment PSA, biopsy grade, and type of therapy were not associated with family history. Kaplan Meier analysis of biochemical failure indicated a 23% worse outcome at three and ®ve years after treatment for those patients with a positive family history (P`0.001) ( Figure  2 ), leading to a relative risk of 1.4 (95% con®dence interval [CI], 1.2 ± 1.7) at 3 y, and 1.8 (95% CI, 1.3 ± 2.4) at 5 years after therapy. Family history remained an independent predictor of outcome in multivariate statistical analysis after adjusting for clinical stage, preoperative PSA, biopsy grade, age and type of therapy (Table 4) .
We also analyzed bRFS in groups strati®ed by tumor characteristics into favorable and unfavorable subsets based on T stage, pre-operative PSA, and biopsy Gleason's sum. The favorable risk group was de®ned as clinical stage T1 or T2, Gleason's sum 6, and PSA ! 10 ng/ml, while the unfavorable risk group was de®ned as clinical stage T3, or Gleason's sum ! 7, or PSA b ng/ml. Positive family history remained associated with worse outcome even in patients with the most favorable tumor characteristics (Table 5) . Among patients undergoing radical prostatectomy, we found no association of family history and adverse pathologic parameters. In particular, men with a family history had similar rates of extracapsular extension, positive margins, Figure 1 Hypothetical paradigm of prostate cancer genotypes. 
Figure 2
Biochemical relapse-free survival by family history in 1038 men with localized disease. Reproduced with permission from Reference 13. In addition to a higher likelihood of positive family history we also observed that a higher proportion of younger patients had favorable tumor characteristics at the time of diagnosis (Table 6 ). This phenomenon is likely due to an increased awareness of prostate cancer risk in those with a family history resulting in earlier presentation for screening and diagnosis. Indeed, of those patients younger than 65 y, 49% of those with a positive family history vs 35% of those with a negative family history (P 0.01) had nonpalpable disease diagnosed by an elevated serum PSA, suggesting that younger patients with a family history were more likely to be screened for prostate cancer.
In a further analysis of an expanded cohort of patients (n 720) treated only by radical prostatectomy we found that positive family history was associated with a higher rate of distant metastasis despite similar tumor characteristics at presentation and on pathologic analysis 13 (Table  7) .
Two recent studies provide further evidence that familial prostate cancer has a more aggressive phenotype. In the ®rst study, Gronberg et al 15 reported on clinical characteristics of prostate cancer in patients linked to HPC1. The tumor characteristics for 74 North American families with hereditary prostate cancer were compared to unlinked prostate cancer cases and to cases from the National Cancer Institute database as a reference comparison. The results demonstrated that affected men in potentially linked families were younger at diagnosis, presented with more advanced stage disease, and had tumors of higher grade than unlinked families. The authors concluded that a substantial fraction of hereditary prostate cancers are diagnosed in advanced stages and emphasized the importance of early detection in men with a family history of prostate cancer. The results also suggest that with extended follow up, the disease outcome for men linked to HPC1 may be worse than those with other forms of prostate cancer because of their more advanced grade and stage at the time of diagnosis.
In a second important study, Rodriguez et al 16 analyzed data from a prospective mortality study of 418 011 men with no history of cancer at enrolment in 1982. In nine years of follow up, they observed 1922 deaths from prostate cancer. De®ning positive family history as an affected ®rst degree relative (father or brother), they observed a relative risk of 1.6 (95% CI, 1.3 ± 1.9) for developing fatal prostate cancer in men with a family history using a Cox proportional hazard model. They also demonstrated that men with two or more affected relatives had a greater than three fold increased risk (relative risk 3.2, 95% CI 1.5 ± 6.7) and that men whose relatives were diagnosed with prostate cancer before age 65 y were at greater risk than men whose relatives were diagnosed at older ages. Several features of this study deserve emphasis. Firstly, this was a large population based study and is, therefore, not affected by selection bias inherent in examining a population of men presenting with localized disease who choose to be treated. Secondly, this study de®ned familial prostate cancer in the same manner as our studies, limiting it to men with a ®rst degree affected relative (brother or father). Perhaps most importantly, the 60% increased risk in the development of fatal prostate cancer still held when other confounding in¯uences were controlled for, including race, education, level of exercise, prior vasectomy, body mass index, smoking history, and vegetable and fat consumption.
Taken together, these four studies 12 ± 15 strongly suggest that familial prostate cancer has a more aggressive course than sporadic disease as manifested by higher grade and advanced clinical stage at the time of presentation, a higher likelihood of distant metastasis after surgical excision, and a higher likelihood of developing fatal prostate cancer. In conjunction with observations in other tumor systems, these observations establish a genetic paradigm for prostate cancer where alterations in the structure or expression of speci®c genes are linked to tumor phenotypes (Table 8) . Evidence already exists for ovarian 17 and breast 18 cancer that mutations in BRCA1 and BRCA2 are associated with tumor behaviour and that disease outcome can be predicted based on individual genotypes. Such evidence also exists for prostate cancer with the observation that fewer CAG repeats in the human androgen receptor gene are associated with more aggressive disease. 19 Further investigation will be necessary to determine whether abnormalities of the HPC1 gene and other genes associated with the development or progression of prostate cancer result in predictable phenotypes.
These observations have important implications for the future management of prostate cancer in men with a family history. Firstly, the observation of more aggressive disease lends strong support to the current American Urological Association and American Cancer Society recommendation for screening men with a family history starting at age 40 y. Two studies in the literature support this recommendation. McWhorter et al 20 screened relatives of patients with at least two affected ®rst degree relatives and found a 24% positive biopsy rate with an expected rate of 3%. In a more recent screening study 21 involving 6390 men with 10% reporting a positive family history in a ®rst degree relative, the positive predictive value for an elevated PSA was 24.6% for those with a positive family history vs 17.9% with those not reporting a family history (P 0.005). These data also create a strong rationale for the development and use of genetic screening which is likely to be more speci®c than PSA screening when the HPC1 and other genes responsible for prostate cancer are identi®ed and cloned. A second important implication of these observations relate to treatment. If men with a family history truly have a more aggressive form of disease than men with sporadic cancer, such men should be treated rather than observed, be treated early at the time of diagnosis rather than at the time of disease progression, and when effective combination therapy is developed, should also be subjected to more aggressive therapy than those with sporadic cancer.
The data reviewed here also have implications with respect to the prevention of prostate cancer. Genetic screening should allow the identi®cation of a population of men at highest risk of developing prostate cancer for the testing of chemopreventative agents. Using a truly high risk population would result in a substantial reduction in the size of the study population necessary to evaluate a preventative agent, shorten the observation time necessary to complete the study, and result in a substantial cost saving compared to standard chemopreventative trials such as the Prostate Cancer Prevention Trial where risk is based on age alone. If leading to promising results, such trials in high risk populations could potentially lead to a recommendation for the use of these agents as prophylactic therapy in genetic carriers.
Conclusions
Current data from single-institution and populationbased studies suggest that men with a family history of prostate cancer have a more aggressive disease than those with sporadic tumors, as evidenced by higher grade and more advanced stage at presentation in those linked to HPC1, higher rates of biochemical failure and distant metastases after therapy for localized disease, and a higher risk of developing fatal prostate cancer. These observations have important implications for screening, treatment, and prevention of this disease.
